ClassID:

2224

A01K2267/0368 - CPC Classification

Classification description:

Animals characterised by purpose; Animal model, e.g. for test or diseases; Animal model for multifactorial diseases Animal model for inflammation

Recent Application in this class:
#1
20260123613
2026-05-07

MOUSE MODEL OF DITRA DISEASE AND USES THEREOF

#2
20260107927
2026-04-23

ZEBRAFISH ANIMAL MODEL FOR INFLAMMATORY DISEASES AND METHOD FOR SCREEING ANTI-INFLAMMATORY AGENTS USING SAME

#3
20250230207
2025-07-17

COMPOSITION

#4
20250134079
2025-05-01

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GENES

#5
20250049740
2025-02-13

COMPOUND AND USE THEREOF IN PREPARATION OF MEDICAMENT FOR TREATING ALZHEIMER'S DISEASE

#6
20240383975
2024-11-21

COMPOSITION FOR TREATING OR PREVENTING IMMUNOLOGICAL ABNORMAL INFLAMMATORY DISEASES

#7
20240299512
2024-09-12

IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE

#8
20240197845
2024-06-20

IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE

#9
20230365988
2023-11-16

MOUSE MODEL FOR BIO-IMAGING OF INFLAMMATORY SIGNALS, PREPARATION METHOD THEREFOR AND USE THEREOF

#10
20230357376
2023-11-09

Method of treating rheumatoid arthritis using antibodies to oxidized phospholipids

#11
20230337642
2023-10-26

METHOD FOR PRODUCING AVATAR MOUSE AS ATOPIC DERMATITIS ANIMAL MODEL AND USE THEREOF

#12
20230172172
2023-06-08

MOUSE MODEL OF DITRA DISEASE AND USES THEREOF

#13
20230027494
2023-01-26

Humanized IL-4 and IL-4Rα animals

#14
20220272953
2022-09-01

GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33

#15
20220132817
2022-05-05

ANIMAL MODEL FOR DRUG DEVELOPMENT

#16
20220033847
2022-02-03

NON-HUMAN ANIMALS EXPRESSING HUMANIZED C1Q COMPLEX

#17
20210368753
2021-12-02

Humanized IL-4 and IL-4Rα animals

#18
20210347890
2021-11-11

CD31SHED AS A MOLECULAR TARGET FOR IMAGING OF INFLAMMATION

#19
20210147521
2021-05-20

VISTA-Ig constructs and the use of VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders

#20
20210100227
2021-04-08

loss of function rodent model

#21
20200146269
2020-05-14

METHODS AND COMPOSITIONS FOR MODULATING INNATE LYMPHOID CELL PATHOGENIC EFFECTORS

#22
20200049696
2020-02-13

Method for producing disease modeling non-human animal, disease modeling non-human animal, and method for screening drug and method for determining risk of disease using the same

#23
20200037587
2020-02-06

Humanized C5 animals

#24
20200022344
2020-01-23

Humanized IL-4 and IL-4Ra animals

#25
20200015462
2020-01-16

Mouse model of DITRA disease and uses thereof

#26
20190380942
2019-12-19

Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH

#27
20190350178
2019-11-21

ANIMAL MODEL FOR DRUG DEVELOPMENT

#28
20190119653
2019-04-25

ADENO-ASSOCIATED VIRUS MEDIATED DELIVERY OF C1EI AS A THERAPY FOR ANGIOEDEMA

#29
20190100802
2019-04-04

MARKER FOR PREDICTING PRESSURE ULCER DEVELOPMENT AND USE THEREOF

#30
20190100772
2019-04-04

Non-human animals expressing humanized C1Q complex

#31
20190092858
2019-03-28

CD31 as a molecular target for imaging of inflammation

#32
20180334498
2018-11-22

Antibodies to oxidized phospholipids

#33
20180334497
2018-11-22

Antibodies to oxidized phospholipids

#34
20180332833
2018-11-22

Humanized C3 animals

#35
20180312607
2018-11-01

Application of PCSK9 inhibitors in the preparation of drugs for the treatment of inflammatory immune diseases

#36
20180310535
2018-11-01

Model animal for fibrosis

#37
20180265576
2018-09-20

Antibodies to oxidized phospholipids

#38
20180255753
2018-09-13

NON-HUMAN MAMMAL

#39
20180243450
2018-08-30

Humanized model of kidney and liver disorders

#40
20180156781
2018-06-07

MODELS, METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY BOWEL DISEASE

#41
20180050097
2018-02-22

IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE

#42
20180042967
2018-02-15

Method for reducing the inflammatory activity of a stem cell transplant and use thereof

#43
20180000056
2018-01-04

Humanized IL-4 and IL-4Rα animals

#44
20170369888
2017-12-28

ADAM12 inhibitors and their use against inflammation-induced fibrosis

#45
20170332611
2017-11-23

Humanized C5 animals

#46
20170311580
2017-11-02

Humanized IL-4 and IL-4Rα animals

#47
20170215394
2017-08-03

Inflammation reporter system

#48
20170135328
2017-05-18

Transgenic mouse expressing kidney-specific human TGF-beta1, and biomarker for tissue fibrosis mouse model

#49
20170107540
2017-04-20

Method of genetically altering and producing allergy free cats

#50
20160374319
2016-12-29

Transgenic non-human mammal that expresses human MMP2

#51
20160347822
2016-12-01

Adeno-associated virus mediated delivery of C1E1 as a therapy for angioedema

#52
20160346186
2016-12-01

Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH

#53
20160345547
2016-12-01

Non-human animals having a disruption in a C9ORF72 locus

#54
20160228468
2016-08-11

Method for reducing the inflammatory activity of a stem cell transplant and use thereof

#55
20160192627
2016-07-07

Transgenic mice expressing human pyrin domain only protein 2

#56
20160083725
2016-03-24

Prophylactic and/or therapeutic agent for inflammatory disease, and method for screening prophylactic and/or therapeutic drug for inflammatory disease

#57
20160057978
2016-03-03

Atopic dermatitis model animal and use thereof

#58
20160037757
2016-02-11

Transgenic model for delay-type hypersensitivity (DTH) and use thereof

#59
20150342164
2015-12-03

ANIMAL MODEL WITH A FILAGGRIN GENE PROMOTER

#60
20150320022
2015-11-12

Humanized IL-4 and IL-4Ra animals

#61
20150320021
2015-11-12

Humanized IL-4 and IL-4Rα animals

#62
20150313194
2015-11-05

Humanized C3 animals

#63
20150296758
2015-10-22

HUMANIZED TRANSGENIC SINGLE NUCLEOTIDE POLYMORPHISM ANIMAL SYSTEMS

#64
20150208620
2015-07-30

Obesity animal model and methods for making and using thereof

#65
20150158940
2015-06-11

Use of antagonists targeting metallothionein to treat intestinal inflammation

#66
20150074835
2015-03-12

TRANSGENIC MOUSE EXPRESSING HUMAN LIPOPROTEIN (A) WITH DISABLED VITAMIN C GENE AND ITS USE AS A DISEASE TREATMENT MODEL

#67
20150047059
2015-02-12

Activity modulator, medicinal agent comprising same, use of CD300A gene-deficient mouse, and anti-CD300A antibody

#68
20150026832
2015-01-22

Inflammation in vivo model

#69
20150026831
2015-01-22

TL1A model of inflammation fibrosis and autoimmunity

#70
20150005367
2015-01-01

ADAM12 inhibitors and their use against inflammation-induced fibrosis

#71
20140056882
2014-02-27

Method of treating pulmonary disease by administering an antibody to G-CSF

#72
20130115226
2013-05-09

Methods and uses of TIE2 binding and/or activating agents

#73
20120225082
2012-09-06

ADAM12 Inhibitors and Their Use Against Inflammation-Induced Fibrosis

#74
20120216303
2012-08-23

NOVEL THERAPEUTIC USES OF HUMAN FORMYL PEPTIDE RECEPTOR ANTAGONISTS

#75
20120204274
2012-08-09

Transgenic mouse conditionally expressing MMP12 for studying myelopoiesis, immunity and tumorigenesis

#76
20120142110
2012-06-07

Method of Genetically Altering and Producing Allergy Free Cats

#77
20120136044
2012-05-31

Compositions And Methods Of Inhibiting NADPH Oxidase Expression

#78
20120079615
2012-03-29

KNOCK-IN MICE WITH INDUCIBLE LOSS OF EOSINOPHILS

#79
20120079611
2012-03-29

TL1A model of inflammation fibrosis and autoimmunity

#80
20120027754
2012-02-02

Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6

#81
20110287007
2011-11-24

Treatment and Prevention of Chronic Asthma Using Antagonists of Integrin AlphavBeta6

#82
20110263691
2011-10-27

Methods concerning PPAR delta and antagonists thereof

#83
20110262441
2011-10-27

Method for selective control of helper T cell function

#84
20110250300
2011-10-13

COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATING TO OXIDATIVE STRESS

#85
20110160438
2011-06-30

IL-17 RECEPTOR LIKE MOLECULES AND USES THEREOF

#86
20110126297
2011-05-26

Transgenic animal with monocyte chemotactic protein 1 promoter

#87
20110099644
2011-04-28

knockout mice and elucidation of association of with early onset degenerative joint disease and role as a tumor suppressor

#88
20110023142
2011-01-27

Genetically modified rat comprising a cytokine gene disruption and exhibiting a greater susceptibility to a cytokine-mediated autoimmune and/or inflammatory disease

#89
20110021599
2011-01-27

Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH

#90
20110016543
2011-01-20

GENOMIC EDITING OF GENES INVOLVED IN INFLAMMATION

#91
20100316624
2010-12-16

TREATMENT OF FIBROSES AND LIVER DISORDERS

#92
20100299766
2010-11-25

MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE

#93
20100287626
2010-11-11

METHOD OF SCREENING PTP ZETA ACTIVITY PROMOTER OR INHIBITOR

#94
20100273854
2010-10-28

COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE EXPRESSION

#95
20100263061
2010-10-14

Properdin Modulation of Alternative Pathway and Uses Thereof

#96
20100251396
2010-09-30

TRANSGENIC MICE EXPRESSING HUMAN FORMYL PEPTIDE RECEPTOR

#97
20100197763
2010-08-05

RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)

#98
20100183640
2010-07-22

METHODS AND COMPOSITIONS FOR THE TREATMENT OF FIBROTIC CONDITIONS AND IMPAIRED LUNG FUNCTION AND TO ENHANCE LYMPHOCYTE PRODUCTION

#99
20100172976
2010-07-08

METHODS AND COMPOSITIONS FOR INHIBITING THE FUNCTION OF POLYNUCLEOTIDE SEQUENCES

#100
20100150841
2010-06-17

Use of Tumor Necrosis Factor-Alpha P75 Receptor for the Reduction of Inflammation

#101
20100138937
2010-06-03

Method for diagnosis of severity and prediction of recurrence in eosinophilic inflammatory disease

#102
20100137405
2010-06-03

RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)

#103
20100107263
2010-04-29

C-REACTIVE PROTEIN (CRP) KNOCKOUT MOUSE

#104
20100058488
2010-03-04

PROTEIN FORMULATIONS COMPRISING S1-5

#105
20100029747
2010-02-04

METHODS AND COMPOSITIONS FOR INHIBITING THE FUNCTION OF POLYNUCLEOTIDE SEQUENCES

#106
20090324591
2009-12-31

Method of treating pulmonary disease by administering an antibody to G-CSF receptor

#107
20090324585
2009-12-31

COMPLEMENT INHIBITORY AGENTS AS THERAPEUTICS IN POSTTRAUMATIC AND DEGENERATIVE ARTHRITIS

#108
20090317388
2009-12-24

Tl1a in treatment of disease

#109
20090312526
2009-12-17

Method for producing antibodies

#110
20090288177
2009-11-19

SGRF gene-modified mouse

#111
20090281287
2009-11-12

IL-17 receptor like molecules and uses thereof

#112
20090156466
2009-06-18

Characterization of a MEKK binding site and uses thereof

#113
20090110676
2009-04-30

BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders

#114
20090081228
2009-03-26

CYR61 COMPOSITIONS AND METHODS

#115
20090029917
2009-01-29

METHODS AND COMPOSITIONS FOR THE TREATMENT OF FIBROTIC CONDITIONS & IMPAIRED LUNG FUNCTION & TO ENHANCE LYMPHOCYTE PRODUCTION

#116
20090028853
2009-01-29

TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN ALPHAvBETA6

#117
20080311185
2008-12-18

Deregulated Genes and/or Processes in Inflammatory Arthritis

#118
20080247994
2008-10-09

DNA vaccine

#119
20080247955
2008-10-09

Inflammation treatment, detection and monitoring via TREM-1

#120
20080241098
2008-10-02

ANTAGONIZING INTERLEUKIN-21 RECEPTOR ACTIVITY

#121
20080194514
2008-08-14

Methods and Compositions for Inhibiting the Function of Polynucleotide Sequences

#122
20080172751
2008-07-17

Method for treating asthma and chronic obstructive pulmonary disease (COPD) comprising administering FGF2

#123
20080167223
2008-07-10

Methods and Compositions for Using Tsh in the Inhibition of Tnf Activity

#124
20080152623
2008-06-26

Blockade of Airway Hyperresponsiveness and Inflammation in a Murine Model of Asthma by Insulin-Like Growth Factor Binding Protein-3 (Igfbp-3)

#125
20080115236
2008-05-15

CBG gene as a genetic marker of hypercortisolism and associated pathologies

#126
20080081792
2008-04-03

Methods and compositions for inhibiting the function of polynucleotide sequences

#127
20080064633
2008-03-13

Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions

#128
20080009447
2008-01-10

Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of SOCS sequence in the animal

#129
20080003212
2008-01-03

ATP Diphosphohydrolase (CD39) Gene Therapy for Inflammatory or Thrombotic Conditions for Transplantation and Means Therefor

#130
20070277252
2007-11-29

Transgenic mouse comprising a polynucleotide encoding human or humanized C5aR and methods of production and use

#131
20070249550
2007-10-25

Modulation of immune response and inflammation by targeting hypoxia inducible factors

#132
20070238178
2007-10-11

Methods and compositions for inhibiting the function of polynucleotide sequences

#133
20070232557
2007-10-04

Methods and compositions for inhibiting the function of polynucleotide sequences

#134
20070219151
2007-09-20

Methods and compositions for inhibiting the function of polynucleotide sequences

#135
20070218037
2007-09-20

Therapeutic agent for fibromyalgia

#136
20070213273
2007-09-13

Vertebrate embryonic pattern-inducing proteins, and uses related thereto

#137
20070154450
2007-07-05

BLOCKING LEUKOCYTE EMIGRATION AND INFLAMMATION BY INTERFERING WITH CD99/HEC2

#138
20070092527
2007-04-26

Proton-sensing g-protein coupled receptors and dna sequences thereof

#139
20070079389
2007-04-05

Method for screening PTPzeta activity promoter or inhibitor

#140
20070036721
2007-02-15

Methods and compositions for in vivo inflammation monitoring

#141
20060286090
2006-12-21

Mediators of epithelial adhesion and their role in cancer and skin disorders

#142
20060263388
2006-11-23

Therapeutic agent for fibromyalgia

#143
20060233709
2006-10-19

Method for identifying novel treatments of inflammatory disease in the gut

#144
20060182733
2006-08-17

ATP diphosphohydrolase (CD39) gene therapy for inflammatory or thrombotic conditions and transplantation and means there for

#145
20060107336
2006-05-18

Nonbacterial prostatitis model animal

#146
20060104956
2006-05-18

Methods and compositions for inhibiting the function of polynucleotide sequences

#147
20060078967
2006-04-13

Antibodies for IL-17 receptor like polypeptides and uses thereof

#148
20060078966
2006-04-13

IL-17 receptor like polypeptides and uses thereof

#149
20060078933
2006-04-13

IL-receptor like molecules and uses thereof

#150
20060051376
2006-03-09

Therapeutic agent for fibromyalgia

#151
20060041948
2006-02-23

Transgenic mice containing chemokine receptor 9A gene disruptions

#152
20060039902
2006-02-23

Antagonizing interleukin-21 receptor activity

#153
20060025348
2006-02-02

Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production

#154
20050255549
2005-11-17

IRAK-4: compositions and methods of use

#155
20050244411
2005-11-03

BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders

#156
20050239202
2005-10-27

Methods and compositions for inhibiting the function of polynucleotide sequences

#157
20050234221
2005-10-20

IL-17 receptor like molecules and uses thereof

#158
20050119209
2005-06-02

Compositions and methods for the treatment and diagnosis of immune disorders

#159
20050090003
2005-04-28

P2x7 receptor-deficient non-human animals and uses thereof

#160
20050039222
2005-02-17

Sgrf gene-modified non-human animals

#161
20050034179
2005-02-10

Non-human mammal model of autoimmune disease having OX40L gene transferred thereinto

#162
20050019260
2005-01-27

Animal model for allergy

#163
20050004028
2005-01-06

Vertebrate embryonic pattern-inducing proteins and uses related thereto